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Objective: To carry out the cross-cultural adaptation of EULAR Sjögren’s Syndrome Patient
Reported Index (ESSPRI) for Portuguese language and evaluate its psychometric properties.
Method: Cross-sectional study of patients with primary Sjögren’s syndrome (SS). The psy-
chometric properties (intraobserver reproducibility and construct validity) were studied. In
construct validity, ESSPRI was compared with the Patient’s Global Assessment (PGA), Proﬁle
of  Fatigue and Discomfort (Profad), Sicca Symptoms Inventory (SSI) and Functional Assess-
ment of Chronic Illness Therapy (Facit-F). Statistical tests used were: Cronbach’s alpha,
intraclass correlation coefﬁcient (ICC), Bland–Altman method and Spearman coefﬁcient.
A  value of p ≤ 0.05 was considered signiﬁcant.
Results: There was no difference between versions in both languages; thus, a Brazilian con-
sensual version was obtained. All subjects were women aged 49.4 ± 11.6 years, with onset
of  symptoms of 7.2 ± 5.4 years, and time of diagnosis of 3.0 ± 3.3 years. The mean ESSPRI
was  6.87 ± 1.97. The intraobserver reproducibility was high and signiﬁcant (0.911) and, with
Bland–Altman method, there was no systematic bias in the agreement of measures among
evaluations. A moderate correlation of ESSPRI with all tested instruments was observed.
 Study conducted at Department of Internal Medicine and Service of Rheumatology, Hospital Universitário Cassiano Antonio Moraes
HUCAM), Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
∗ Corresponding author.
E-mail: val.valim@gmail.com (V. Valim).
ttp://dx.doi.org/10.1016/j.rbre.2015.08.001
255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
440  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(5):439–445
Conclusion: The Brazilian Portuguese version of ESSPRI is a valid and reproducible version.
©  2015 Elsevier Editora Ltda. All rights reserved.
Validac¸ão  e  propriedades  psicométricas  do  Eular  Sjögren’s  Syndrome
Patient  Reported  Index  (ESSPRI)  para  a  língua  portuguesa
Palavras-chave:
Síndrome de Sjögren
Escalas
Estudos de validac¸ão
Esspri
r  e  s  u  m  o
Objetivo: Fazer a adaptac¸ão transcultural do Eular Sjögren’s Syndrome Patient Reported
Index  (Esspri) para a língua portuguesa e avaliar as suas propriedades psicométricas.
Método: Estudo transversal de pacientes com síndrome de Sjögren primária (SS). Foram
estudadas as propriedades psicométricas (reprodutibilidade intraobservador e a validade
de  construto). Na validade de construto, o ESSPRI foi comparado com o Patient’s Global
Assessment (PaGA), Proﬁle of Fatigue and Discomfort (Profad), Sicca Symptoms Inventory
(SSI) e Functional Assessment of Chronic Illness Therapy (Facit-fatigue). Os testes estatís-
ticos usados foram o -Cronbach, coeﬁciente de correlac¸ão intraclasse (CCI), método de
Bland-Altman e coeﬁciente de Spearman. Foi considerado signiﬁcativo o p ≤ 0,05.
Resultados: Não houve diferenc¸a entre as versões nas duas línguas e obteve-se, assim, a
versão consensual brasileira. Todos os indivíduos foram mulheres de 49,4 ± 11,6 anos, com
início  dos sintomas de 7,2 ± 5,4 anos e tempo de diagnóstico de 3 ± 3,3 anos. A média do
Esspri  foi de 6,87 ± 1,97. A reprodutibilidade intraobservador foi alta e signiﬁcativa (0,911) e,
no  método de Bland-Altman, não houve viés sistemático na concordância das medidas entre
as  avaliac¸ões. Houve correlac¸ão moderada do Esspri com todos os instrumentos testados.
Conclusão: A versão do Esspri em português é válida e reprodutível.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Sjögren’s syndrome (SS) is an autoimmune, chronic syndrome
with slow and progressive evolution. SS is considered as
the second most common autoimmune rheumatic disease,
affecting 0.17% of Brazilian population,1 similar to other Euro-
pean studies using the American-European criterion (2002)
for diagnostic classiﬁcation.2,3 SS is morphologically charac-
terized by a lymphocytic inﬁltrate in salivary and lacrimal
glands,4,5 but 20–40% of patients present extraglandular man-
ifestations in musculoskeletal, pulmonary, gastrointestinal,
hepatic, hematologic, vascular, dermatological, renal, and
neurological systems.4–7
Quality of life is impaired in different aspects: physical, psy-
chological and social, as a result of dryness and extraglandular
manifestations.7–15 Although SS is a prevalent disease with
great impact, there is little evidence for its treatment. In the
last decade, many  new drugs, especially those pertaining to
the class of biological agents, have been developed and it is
expected that these drugs can be tested in this disease. In this
context, the European League Against Rheumatism (EULAR)
developed the EULAR Sjögren’s Syndrome Patient Reported
Index (ESSPRI), a measuring instrument that has been used
as an endpoint in clinical trials to evaluate the subjective per-
ception of the patient with respect to the most important and
frequent symptoms, such as fatigue, pain and dryness, and
their impact on the disease.16,17 Previous instruments such
as the Proﬁle of Fatigue and Discomfort (PROFAD),18 the Sicca
Symptoms Inventory (SSI)19 and the short version of the Pro-
ﬁle of Fatigue and Discomfort – Sicca Symptoms Inventory(PROFAD-SSI)20 have the limitation of assessing only an aspect
of this disease (only fatigue/pain, or only dryness), whereas
ESSPRI gathered in a single composite index these three symp-
toms.
ESSPRI is completed by the patient and it contains just three
items to be given an activity level score between 0–10: pain,
fatigue and dryness, the ﬁnal ESSPRI score is the mean of all
three scores and therefore also between 0–10. ESSPRI was pre-
liminary validated by a multicenter study in 201116 and 2014.21
This instrument has reproducibility = 0.94, and its sensitivity
to change is low (−0.37), but signiﬁcantly higher when com-
pared to SSI (p = 0.006) and PROFAD (p = 0.049).21 After 16, 24,
36 and 60 weeks of treatment with rituximab, ESSPRI showed
signiﬁcant improvement (decrease of the patient’s symptoms)
compared to the initial evaluation.22
Currently, ESSPRI is being extensively used and has shown
a correlation with quality of life23 and functional status24
measures, and can be considered a useful predictor of health
status of patients with pSS.25
The aim of this study was to carry out a cross-cultural adap-
tation of ESSPRI into Portuguese language and to evaluate its
psychometric properties (Annex 1).
Patients  and  methods
This was a cross-sectional study approved by the Research
Ethics Committee of the Health Sciences Center, Universidade
Federal do Espírito Santo, under Opinion number 008/10 on
February 24, 2010. All patients were informed about the objec-
tives of this study and signed the an Informed Consent Form.
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In the evaluation stage of semantic equivalence, a pre-test
with the consensual version of ESSPRI (Table 1) was carried
out. The test was applied to 20 patients and there were no “not
Table 1 – Clinical and demographic characteristics of 62
patients with primary Sjögren syndrome.
Variable n (%) Mean ± SD
Age (years) 49.4 ± 11.6
<50 25 (40.3)
≥50 37 (59.7)
Female gender 62 (100)
Elapsed time from early symptoms
(years)
7.2  ± 5.4
<1 4 (6.5)
1–5 25 (40.3)
>5 33 (53.2)
Diagnostic time (years) 3.0 ± 3.3
<1 16 (25.8)
1–5 40 (64.5)
>5 6 (9.7)
Interval between symptoms and
diagnosis (years)
4.3  ± 4.9
<1 18 (29)
1–5 27 (43.6)
>5 17 (27.4)
Systemic manifestations in last visit 29 (46.8)
Systemic manifestations in previous
visits
38 (61.3)
Inactive disease 29 (46.8)
Active disease
Low activity 24 (38.7)
Moderate activity 9 (14.5)
Clinical features:
Objective xerophthalmia
(Schirmer test and/or Rose Bengal
stain)
48 (77.4)
Objective xerostomia (salivary
ﬂow/salivary gland scintigraphy)
53 (85.5)
Sialadenitis, lymphocytic ≥1
focus-score
56 (90.3)
Anti-Ro/SSA antibody 27 (43.6)
Anti-La/SSB antibody 12 (19.4)r e v b r a s r e u m a t o l
atients
he study sample consisted of subjects with SS coming
rom the Sjögren’s Syndrome Outpatient Clinic, Rheumatology
epartment, Hospital Universitário Cassiano Antônio Moraes
HUCAM), in Vitória-ES.
ethods
nclusion  and  exclusion  criteria
atients included fulﬁlled the following criteria: diagnosed
ith SS according to European-American Criteria (2002) for the
lassiﬁcation of this disease; aged over 18 years old; and agreed
o participate. Subjects with other autoimmune diseases, cir-
hosis, sarcoidosis, known hepatitis C infection, acquired
mmunodeﬁciency syndrome, preexisting lymphoma, graft
ersus host disease; head and neck radiation in the past; and
revious use of anticholinergic drugs, were excluded.
omains  and  calculation  of  ESSPRI
he ESSPRI questionnaire consists of three items to be given
n activity level score between 0–10: pain (joint and/or mus-
le pain), fatigue and dryness (0 = no symptom at all and
0 = worst symptom imaginable. The patient must check the
lternative that best describes the severity of his/her symp-
oms in the worst stages in the last two weeks. Each domain
epresents the severity of the symptom independently; how-
ver, it is also possible to obtain a ﬁnal score by averaging the
cores of the three domains.
Although the instrument is self-administered, it was
ecided in this study to use only a face-to-face interview, in
iew of the low education level of participants.
ranscultural  adaptation
o test the equivalence (conceptual, of the item, semantic and
perational) of ESSPRI, an international methodology was fol-
owed to generate the consensus version into Portuguese,26 a
ethod also used by other Brazilian authors.27–31
sychometric  properties.  The psychometric properties veriﬁed
ere: internal consistency, intraobserver reproducibility, and
onstruct validity. To test reproducibility, ESSPRI was applied
wice by the same observer (intraobserver evaluation), with
n interval of 2 days between the ﬁrst and the second eval-
ation, taking into account that this is an instrument based
nly on the subjective perception of the patient’s symptoms.
o access construct validity, we  studied the correlation power
etween ESSPRI and PROFAD,18 SSI,19 Functional Assessment
f Chronic Illness Therapy (FACIT-F) and subjective perception
f disease activity by the patient through the use of a visual
cale (Patient’s Global Assessment – PGA).16
tatistical  analysis
o study the semantic equivalence, a sample of 20 patients was
sed. There is no mathematical formula for a sample calcula-
ion at this stage, and small samples are considered sufﬁcient
or this qualitative analysis.31 As for the study of psychomet-
ic measurement properties (validation and reproducibility),
he sample was calculated based on the use of at least ﬁve 5;5 5(5):439–445 441
patients per domain of the instrument.32 The minimum cal-
culated sample was 15 patients.
To evaluate psychometric properties,27–30 the following
analyzes were performed: (1) Cronbach’s alpha for internal
consistency; (2) intraclass correlation coefﬁcient (ICC) and the
graphic method of Bland–Altman statistics for intraobserver
reproducibility; (3) Spearman correlation coefﬁcient of ESSPRI
versus PGA, PROFAD, SSI and FACIT-F for construct validity.
In statistical analysis, the software SPSS 19.0 was used, and
a p value ≤0.05 was considered signiﬁcant.
ResultsPrevious parotid glandular
swelling
16  (25.8)
SD, standard deviation.
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Table 2 – Results of agreement between evaluations on
each question and ESSPRI total score.
Questions ICC
Dryness 0.773
Fatigue 0.870
Pain 0.770
ESSPRI total score 0.911
ICC, intraclass correlation coefﬁcient; ESSPRI, EULAR Sjögren’s Syn-
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Fig. 1 – Concordance of measures of ﬁnal ESSPRI scoredrome Patient Reported Index.
understood” questions to more  than 15% of patients; thus, this
was considered the ﬁnal version of ESSPRI for the Portuguese
language.
Sixty-two women with SS were included to evaluate the
psychometric properties. The mean age was 49.4 ± 11.6 years,
with predominance of participants over 50 years old. As for
ethnicity, 43.56% were Brown, 32.25% Caucasian, and 24.19%
of African descendent. The majority (56.41%) had low lev-
els of education (<8 years), and 8.06% were illiterate. The
duration of disease was 7.2 ± 5.4 years, 46.8% of patients had
some systemic manifestation and 87.1% had already used
immunosuppressive drugs in the past. Most patients had an
inactive disease (46.8%) and 38.7% showed low disease activ-
ity, according to the physician’s subjective judgment (Table 1).
The diagnostic classiﬁcation criteria frequency6 is described
in Table 1.
The questionnaire was answered easily by 59.67% of
patients (score ≤3). The mean degree of difﬁculty to answer
the ESSPRI questionnaire was 2.84 ± 3.05, on a scale of
0–10. The mean for ESSPRI was 6.87 ± 1.97 on a scale of
0–10.
The internal consistency of ESSPRI was weak, resulting in
a Cronbach’s alpha value corresponding to 0.447. The intra-
observer reproducibility for this instrument was high and
signiﬁcant (0.911). With the use of the Bland–Altman method
(Fig. 1), it was observed that there was no systematic bias in
the agreement of the measures between interviews, because
of the good distribution of data throughout its extension. Most
measurements were distributed within acceptable limits of
variation, with only two points outside the standard deviation
Table 3 – Results of correlation of ESSPRI with PGA, SSI, PROFAD
ESSPRI results 
Correlation coefﬁcient p-value C
ESSPRI 1 0.000 
PGA 0.602a 0.000 
SSI 0.444a 0.000 
PROFAD 0.492a 0.000 
FACIT 0.551a 0.000 
PROFAD-SSI 0.527a 0.000 
PGA, patient’s global assessment; FACIT, functional assessment of chronic
symptoms inventory; SSI, Sicca Symptoms Inventory; PROFAD, proﬁle of 
Reported Index; SD, standard deviation.
a Statistically signiﬁcant Spearman correlation coefﬁcients.between evaluations 1 and 2. Bland–Altman graph.
range of ±1.96 (outliers), but near the limits, indicating that
measures between interviews tend to produce similar results.
The reproducibility of each question of ESSPRI was tested
separately, with high concordance for all questions (Table 2).
It is observed from Table 3 the existence of a moderate and
signiﬁcant correlation of ESSPRI with all tested instruments.
The correlation was positive, that is, when the ESSPRI score
increases, the other scores also increase.
Discussion
Recently, ESSDAI (EULAR Syndrome Sjögren’s Disease Activity
Index), an instrument for evaluation of disease activity based
on objective criteria and evaluation by the physician,32 and
PROFAD-SSI,33 an instrument that foregoes the development
of ESSPRI, were translated and validated into Portuguese lan-
guage. However, nowadays ESSPRI is the most widely used
instrument worldwide in the subjective assessment of SS
severity of symptoms, according to the patient’s perception,
with the advantage of being faster to be answered.
ESSPRI was originally developed including 10 questions,
with three global scales (dryness, fatigue and pain), one scale
, FACIT and PROFAD-SSI instruments.
PGA results Mean ± SD
orrelation coefﬁcient p-value
0.602a 0.000 6.87 ± 1.97
1 0.000 7.58 ± 2.15
0.426a 0.000 18.19 ± 6.40
0.498a 0.000 18.67 ± 6.23
0.455a 0.000 30.73 ± 11.35
0.521a 0.000 4.61 ± 1.41
 illness therapy; PROFAD-SSI, proﬁle of fatigue and discomfort – sicca
fatigue and discomfort; ESSPRI, EULAR Sjögren’s Syndrome Patient
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n mental fatigue and 6 scales on dryness (eye, mouth, vagina,
kin, nose, airways and respiratory). In the multicenter vali-
ation study, it was observed that the psychometric properties
f the three global scales were as good as the overall instru-
ent and, therefore, its ﬁnal version was limited to those
 global scales.16 This study was developed in parallel with
he multicenter study for ESSPRI validation, and therefore the
omplete instrument was applied and tested; and our analysis
re consistent with international data.21 Thus, the psycho-
etric properties of the ﬁnal instrument with only 3 global
cales are comparable to the preliminary instrument with 10
uestions. However, the ﬁnal instrument is less detailed in
elation to dryness in each organ.
The construct validity of the original version of ESSPRI
howed moderate correlation with PROFAD (r = 0.73), SSI
r = 0.66) and PGA (r = 0.70),16 and the same was observed for
he current version in the multicenter validation, r = 0.68,
 = 0.59 and r = 0.70, respectively.21 Although correlation
oefﬁcients are slightly lower, the present study also showed
oderate correlation with the same instruments.
The composite score of PROFAD-SSI, though not validated
n its original version, but validated for the Portuguese Brazil-
an version,33 showed a moderate correlation (0.527) with
SSPRI, a value very close to that found in the validation study
f the Brazilian version of PROFAD-SSI (r = 0.545).33
The high reproducibility found in this study (0.911) was
imilar to that of the multicenter study (0.94).21 On the
ther hand, the low internal consistency of the instrument
as expected, since the three domains characterize different
spects of the disease and do not always converge.
The sample consisted of women in the 5th decade of life,
ith their disease lasting 7.2 years, similar to the demographic
roﬁle of other cohorts6,34–38 and to that in the ESSPRI devel-
pment study.16
Due to the low education level and to the illiteracy of a
arge part of the Brazilian population, research in health care
sually gives priority to interviews in gathering information.28
herefore, the authors decided by a change in the form of
pplication of the self-administered questionnaire, choosing
 face-to-face interview model. This change does not invali-
ate the use of this instrument by self-administration,29 and
he psychometric equivalence obtained between the original
nd the translated version conﬁrmed the suitability of this
nstrument.
In our sample, 43.5% of anti-Ro and/or anti-La positives
ere found, a slightly lower frequency than that in other 5;5 5(5):439–445 443
studies.6,16,34–37 Despite the low antibody frequency, the diag-
nosis was well established, as all patients underwent salivary
biopsy and met  the American-European criteria. The fre-
quency of biopsies with a focus score ≥1 was 90.3%. This
lower antibody frequency can be related to a less severe
disease and could partially explain the low disease activity
in most subjects in the sample. The antibody identiﬁca-
tion was carried out by double immunodiffusion method,
which has a lower sensitivity than other methods, such as
ELISA. Furthermore, the sample came from a unit where an
active search is performed for all cases of dryness and biop-
sies are systematically obtained. For this reason, many  mild
cases that otherwise would be underdiagnosed (antibody-
negatives, without systemic manifestations) are part of the
sample.
Various tools have been developed and validated to assess
the subjective characteristics in different autoimmune dis-
eases and their implications in the quality of life.39 In SS,
the symptoms of fatigue, pain, and dryness40 might exert
high impact on the perception of illness and quality of
life.
Interestingly, while most of the sample studied was made
up of low-activity patients, the ESSPRI score was high. This dis-
sociation was already detected in previous studies, suggesting
that the patient’s symptoms and systemic complications are
two different components of the disease, reinforcing the idea
that both should be evaluated, but separately.21,41–44
Conclusion
ESSPRI evaluates the patient’s symptoms with SS and is an
adaptable, reproducible and valid instrument for the Por-
tuguese language, and can be used in the Brazilian context.
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Annex  1.  Final  version  of  EULAR  Sjögren’s  Syndrome  Patients  Reported  Index  (ESSPRI).
Your doctor asked you to answer some questions rela ted to you r disea se. To  answer the 
your symptoms of severity the consider please questions,  only stages, worst the in 
during the last two weeks.  
Please check the alternative that best describes you r answer. Plea se answer all  qu estion s 
carefull y.  
Example: 
No pain  
                    
0       1       2       3      4       5       6       7      8       9      10 Maximal imaginable 
pain  
1) How severe has your  dryness been during the last 2 wee ks? 
No dryness                     
0       1       2       3      4       5       6       7      8       9      10 
 Maximal 
imaginable 
dryness 
2) How severe has your  fatigue been during the last 2 wee ks?  
No fatigue 
                    
0       1       2       3      4       5       6       7      8       9      10 
Maximum 
imaginable fatigue
3) How severe has your  pain (joint or muscular pain,  in  you r arms or legs) been during 
the last 2 wee ks? 
No pain 
                    
0       1       2       3      4       5       6       7      8       9      10 
Maximal 
imaginable pain 
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